Baillie Gifford & CO Ab Cellera Biologics Inc. Transaction History

Baillie Gifford & CO

  • $128 Billion
  • Q3 2025

A detailed history of Baillie Gifford & CO transactions in Ab Cellera Biologics Inc. stock. As of the latest transaction made, Baillie Gifford & CO holds 10,422,966 shares of ABCL stock, worth $55.9 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
10,422,966
Previous 10,360,004 0.61%
Holding current value
$55.9 Million
Previous $35.5 Million 47.54%
% of portfolio
0.04%
Previous 0.03%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Oct 31, 2025
BUY
$3.49 - $5.15 $219,737 - $324,254
62,962 Added 0.61%
10,422,966 $52.4 Million
Q2 2025

Aug 06, 2025
SELL
$1.93 - $3.8 $1.61 Million - $3.18 Million
-835,828 Reduced 7.47%
10,360,004 $35.5 Million
Q1 2025

May 07, 2025
SELL
$2.2 - $3.53 $2.29 Million - $3.67 Million
-1,040,633 Reduced 8.5%
11,195,832 $25 Million
Q4 2024

Jan 31, 2025
SELL
$2.48 - $3.15 $1.63 Million - $2.07 Million
-658,238 Reduced 5.1%
12,236,465 $35.9 Million
Q3 2024

Nov 05, 2024
SELL
$2.39 - $3.49 $21.5 Million - $31.5 Million
-9,016,311 Reduced 41.15%
12,894,703 $33.4 Million
Q2 2024

Jul 25, 2024
SELL
$2.73 - $4.73 $3.46 Million - $6 Million
-1,269,075 Reduced 5.47%
21,911,014 $64.9 Million
Q1 2024

May 01, 2024
SELL
$4.29 - $5.97 $3.71 Million - $5.16 Million
-864,707 Reduced 3.6%
23,180,089 $105 Million
Q4 2023

Jan 26, 2024
SELL
$3.91 - $5.93 $8.45 Million - $12.8 Million
-2,159,853 Reduced 8.24%
24,044,796 $137 Million
Q3 2023

Nov 13, 2023
SELL
$4.6 - $7.95 $736,469 - $1.27 Million
-160,102 Reduced 0.61%
26,204,649 $121 Million
Q2 2023

Jul 28, 2023
BUY
$5.66 - $7.59 $37 Million - $49.6 Million
6,535,100 Added 32.96%
26,364,751 $170 Million
Q1 2023

May 03, 2023
BUY
$7.31 - $11.18 $971,615 - $1.49 Million
132,916 Added 0.67%
19,829,651 $150 Million
Q4 2022

Jan 24, 2023
BUY
$9.48 - $14.52 $60.1 Million - $92 Million
6,339,067 Added 47.46%
19,696,735 $200 Million
Q3 2022

Oct 27, 2022
BUY
$9.2 - $13.68 $27,167 - $40,397
2,953 Added 0.02%
13,357,668 $132 Million
Q2 2022

Aug 08, 2022
BUY
$5.72 - $10.65 $13.2 Million - $24.6 Million
2,305,950 Added 20.87%
13,354,715 $142 Million
Q1 2022

May 05, 2022
BUY
$7.46 - $14.14 $55.8 Million - $106 Million
7,474,857 Added 209.15%
11,048,765 $108 Million
Q4 2021

Jan 20, 2022
BUY
$12.99 - $17.73 $4.33 Million - $5.91 Million
333,365 Added 10.29%
3,573,908 $51.1 Million
Q3 2021

Oct 19, 2021
BUY
$14.85 - $21.34 $7.65 Million - $11 Million
515,346 Added 18.91%
3,240,543 $64.9 Million
Q2 2021

Aug 02, 2021
BUY
$20.19 - $34.17 $31.7 Million - $53.6 Million
1,569,844 Added 135.88%
2,725,197 $60 Million
Q1 2021

May 06, 2021
BUY
$23.29 - $53.2 $26.9 Million - $61.5 Million
1,155,353 New
1,155,353 $39.2 Million

Others Institutions Holding ABCL

# of Institutions
148
Shares Held
115M
Call Options Held
488K
Put Options Held
476K
View Full List

About AbCellera Biologics Inc.

ABCL Quotes by TradingView
  • Ticker ABCL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 285,139,008
  • Market Cap $1.53B
  • Description
  • AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in ...
More about ABCL
Track This Portfolio

Track Baillie Gifford & CO Portfolio

Follow Baillie Gifford & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Baillie Gifford & CO, based on Form 13F filings with the SEC.

News

Stay updated on Baillie Gifford & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email